Recovery after l-DOPA treatment in peginterferon and ribavirin induced parkinsonism
- 作者：A. Bersano ; A. Aghemo ; M.G. Rumi ; E. Ballabio ; L. C ; elise ; M. Colombo
- 关键词：Parkinsonism ; HCV ; PegInterferon ; Levodopa ; Side effects
- 刊名：European Journal of Internal Medicine
- 出版年：2008
- 期刊代码：91_09536205
- 类别：med
- 出版时间：July 2008
- 卷：19
- 期：5
- 页码：370-371
- 文件大小：93 K
摘要
Hepatitis C virus (HCV) chronically infects approximately 2%of the European population. Antiviral therapy with pegInterferon-
(PegIFN) and ribavirin (Rbv) is the standard of care, leading to HCV eradication in roughly 50%of patients. IFN-based therapy has been associated with high rates (20%) of central nervous system side effects, but only a few case reports exist on extrapyramidal side effects.
(PegIFN) and ribavirin (Rbv) is the standard of care, leading to HCV eradication in roughly 50%of patients. IFN-based therapy has been associated with high rates (20%) of central nervous system side effects, but only a few case reports exist on extrapyramidal side effects.